Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.38 |
| ▸ | NPY4R | P50391 | 4/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.36 |
| ▸ | NPY1R | P25929 | 3/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | NMT2 | O60551 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20340675 | 0.91 | NMT1 (0.43) | PTGS1PTGS2NPY4RNPY5RNPY1R | |
| SCHEMBL22668934 | 0.90 | NPY4R (0.38) | PTGS1PTGS2NPY4RNPY5RNPY1R | |
| SCHEMBL18932741 | 0.90 | PTGS1 (0.46) | PTGS1PTGS2PTPN1ITGB3ITGA2B | |
| SCHEMBL17722910 | 0.90 | PTGS1 (0.46) | PTGS1PTGS2PTPN1ITGB3ITGA2B | |
| SCHEMBL23436462 | 0.90 | NMT1 (0.46) | NPY4RNPY5RNPY1RNPY2RNMT2 | |
| SCHEMBL20889000 | 0.90 | NMT1 (0.46) | NPY4RNPY5RNPY1RNPY2RNMT2 | |
| SCHEMBL20935160 | 0.90 | SMN1; SMN2 (0.41) | PTPN1ITGB3ITGA2BNPY4RNPY5R | |
| SCHEMBL19681467 | 0.89 | PTGS1 (0.45) | PTGS1PTGS2PTPN1ITGB3ITGA2B | |
| SCHEMBL21474404 | 0.89 | PTGS1 (0.45) | PTGS1PTGS2PTPN1ITGB3ITGA2B | |
| SCHEMBL20889018 | 0.89 | PTGS1 (0.45) | PTGS1PTGS2PTPN1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230037682-A1 | BINDING MOLECULES AGAINST CD3 AND USES THEREOF | NOVARTIS AG (CH) | 2023-02-09 | — | — | US | disclosed |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2022-12-15 | — | — | US | disclosed |
| US-20210163620-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | NOVARTIS AG (CH) | 2021-06-03 | — | — | US | disclosed |
| US-20200362054-A1 | TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENTS AND USE THEREOF | NOVARTIS AG (CH) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | CD44, SIGLEC7, SIGLEC9 | PTGS1 4599/4885PTGS2 4573/4885PTPN1 2594/4885 |
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | PTGS1 3958/4885PTGS2 4271/4885PTPN1 519/4885 |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | EPCAM, CD40, BCR | PTGS1 3270/4885PTGS2 3806/4885PTPN1 1373/4885 |
| US-20200362054-A1 | TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENTS AND USE THEREOF | CD2, CD2BP2, CD22 | PTGS1 3904/4885PTGS2 4095/4885PTPN1 252/4885 |
| US-20210163620-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | CD2, CD4, CD22 | PTGS1 4645/4885PTGS2 4655/4885PTPN1 507/4885 |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | CD2, CD2BP2, CD22 | PTGS1 4454/4885PTGS2 4662/4885PTPN1 560/4885 |
| US-20230037682-A1 | BINDING MOLECULES AGAINST CD3 AND USES THEREOF | CD2, CD4, CD14 | PTGS1 3616/4885PTGS2 4241/4885PTPN1 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.